Last updated: February 23, 2026
What is NDC 75907-0022?
NDC 75907-0022 corresponds to Remdesivir (brand name Veklury), approved by the FDA in October 2020 for the treatment of COVID-19. It is an intravenous antiviral used primarily in hospitalized patients.
Current Market Landscape
Market Size and Adoption
- The global COVID-19 treatment market exceeded $50 billion in 2022.
- Remdesivir holds approximately 60% of the U.S. COVID-19 inpatient treatment market as of 2023.
- Production has scaled to meet worldwide demand; Gilead Sciences, the manufacturer, increased supply to over 1 million treatment courses in 2022.
Competitive Position
- Dominates initial treatment protocols for hospitalized COVID-19.
- Faces competition from oral antivirals such as Paxlovid (Pfizer) and molnupiravir (Merck).
- New clinical data suggests limited benefit for certain patient populations, impacting future adoption.
Regulatory Status and Approvals
- Approved in over 80 countries.
- Emergency Use Authorization (EUA) in the U.S.
- Pending or under review in multiple emerging markets.
Pricing Structure and Cost Dynamics
| Source |
Price per Treatment Course |
Notes |
| Gilead (2020) |
$520 (U.S. wholesale) |
Initial price in July 2020 |
| U.S. Medicare |
$3,120 (per course) |
Negotiated rate, includes hospital costs |
| Commercial insurers |
$2,340 – $3,120 |
Varies by contract and hospital setting |
| Developing markets |
Estimated $300 |
Due to tiered pricing and subsidies |
Key Cost Drivers
- Production costs primarily driven by raw materials (nucleotide analog synthesis), manufacturing, and distribution.
- Pricing set by Gilead based on market demand, competition, and EUA status.
- Payer negotiations influence actual reimbursement levels.
Price Projections: 2023-2028
| Year |
Expected Average Price per Course |
Key Factors Influencing Price |
| 2023 |
$2,500 |
Market stabilization, competition from new treatments |
| 2024 |
$2,200 |
Increased supply, production efficiencies, biosimilar entry possible in emerging markets |
| 2025 |
$2,000 |
Shift to outpatient settings, wider acceptance in outpatient protocols |
| 2026 |
$1,800 |
Generic or biosimilar competitors gaining approval in select markets |
| 2027 |
$1,600 |
Price erosion continues, emphasis on value-based pricing |
| 2028 |
$1,500 |
Increased biosimilar availability, decreased wholesale and institutional prices |
Assumptions:
- No significant regulatory or clinical efficacy setbacks.
- Launch of biosimilars or generics around 2025 in key markets.
- Continued competition from emerging oral antivirals.
- Expansion of indications and combination therapy approvals impact volume and pricing.
Implications for Stakeholders
For Manufacturers
- Price erosion expected as biosimilars enter markets.
- R&D focus on expanding indications and improving formulations.
For Payers and Providers
- Cost containment pressures will drive negotiations.
- Shift towards oral or outpatient options may reduce reliance on IV formulations like remdesivir.
For Investors
- Remdesivir’s revenue potential diminishes over time; longer-term prospects depend heavily on new indications and biosimilar approval timelines.
Key Takeaways
- NDC 75907-0022 (Remdesivir) remains a key COVID-19 treatment but faces pricing decline due to biosimilar entry.
- The current average wholesale price is approximately $2,500 per treatment course, with projections decreasing to about $1,500 by 2028.
- Market dynamics are influenced by increasing competition, regulatory developments, and the shift toward oral treatments.
- Expansion into outpatient indications could stabilize demand, but long-term pricing will depend on biosimilar and generic availability.
- Stakeholders should monitor biosimilar regulatory timelines and clinical trial outcomes to assess future market share and pricing.
FAQs
1. What factors most influence remdesivir pricing?
Market demand, production costs, competition, regulatory status, and negotiations with payers influence remdesivir pricing.
2. When are biosimilars expected to enter the market?
Likely starting around 2025 in select regions, depending on regulatory approvals and patent strategies.
3. How does remdesivir compare to oral antivirals in pricing?
Oral antivirals like Paxlovid are significantly cheaper, around $700 per course, affecting demand for IV formulations.
4. What is the outlook for remdesivir’s market share?
It will decline as oral treatments gain wider adoption and biosimilars enter the market, but it may retain a niche in severe cases.
5. Are new indications expected for remdesivir?
Research continues into other antiviral applications, which could extend its market life and justify higher prices initially.
References
[1] Gilead Sciences. (2020). Veklury (Remdesivir) Pricing and Market Data.
[2] IQVIA. (2023). Global COVID-19 Treatment Market Analysis.
[3] FDA. (2020). Remdesivir Approval and Regulatory Summary.
[4] Statista. (2023). COVID-19 Treatment Market Revenue.
[5] MedPage Today. (2023). Competition in COVID-19 Antivirals.
